Oncolytics Biotech Inc. (ONCY) Stock

Oncolytics Biotech Inc. (ONCY) is a Healthcare stock trading at $0.95 (as of 2026-06-18), with a market capitalization of $124.13M and a trailing P/E of -2.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on discovering and developing treatments for cancer. Its lead candidate is pelareorep, an intravenous immunotherapeutic for solid tumors and hematological malignancies, and it is being co-developed with Merck KGaA and Pfizer, including in combination regimens for metastatic breast cancer.

Valuation — source: SEC EDGAR (first-party)
Price	$0.95
Market Cap	$124.13M
P/E Ratio	-2.9
EV / EBITDA	-3.2
Price / Book	-21.64
Price / Sales	354.63
DCF Value (model)	$-2.90
DCF Upside vs Price	-405.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$386000.00
Net Margin	-7450.5%
Return on Equity	648.9%
Current Ratio	1.38
Revenue Growth (YoY)	-62.4%
EPS Growth (YoY)	33.3%
FCF Growth (YoY)	54.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	-85.82 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-113.9%
vs Industry	-117.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RENAISSANCE TECHNOLOGIES LLC ($607603.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jared Kelly
Employees	28
Country	CA
IPO Date	2001-10-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.